Overview
1983Founded1
Compare with Q/C TECHNOLOGIES, INC., VOLITIONRX LTD or Insight Molecular Diagnostics Inc., or pick any stock.
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
-18599.8%Operating margin5
-16748.0%Net margin5
-78.0%Revenue growth, 20255
-49.1%Return on equity5
-$213.7MFree cash flow5
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Products and services
Grant brought in 94% of the revenue Celldex Therapeutics broke down this way in fiscal 2025.
Products and services by year
| Products and services | 2023 | 2024 | 2025 |
|---|---|---|---|
| Grant | $6.6M | $7.0M | $1.4M |
| Service | $278.0K | $13.0K | $97.0K |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue0¢$200.0K
- Research and development100¢$245.1M
Out of $1.5M in revenue.5 The company lost money this year.
Financial statements
Every line of the income statement as filed: the last 3 fiscal years, latest first.5
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Total revenues | $1.5M | $7.0M | $6.9M |
| Research and development | $245.1M | $163.6M | $118.0M |
| General and administrative | $43.8M | $38.5M | $30.9M |
| Litigation settlement related loss | $12.5M | ||
| Total operating expenses | $288.9M | $202.1M | $161.4M |
| Operating loss | -$287.4M | -$195.1M | -$154.5M |
| Investment and other income, net | $28.6M | $37.2M | $13.1M |
| Basic net loss per common share (in dollars per share) | -$3.90 | -$2.45 | -$2.92 |
| Diluted net loss per common share (in dollars per share) | -$3.90 | -$2.45 | -$2.92 |
| Shares used in calculating basic net loss per share (in shares) | 66.4M shares | 64.4M shares | 48.4M shares |
| Shares used in calculating diluted net loss per share (in shares) | 66.4M shares | 64.4M shares | 48.4M shares |
| Net loss | -$258.8M | -$157.9M | -$141.4M |
| Unrealized gain on marketable securities | $312.0K | $6.0K | $2.0M |
| Comprehensive loss | -$258.4M | -$157.9M | -$139.4M |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.5
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $28.9M | $28.4M | ||
| Marketable securities | $489.7M | $696.9M | ||
| Accounts and other receivables | $2.0M | $700.0K | ||
| Prepaid and other current assets | $14.1M | $21.2M | ||
| Total current assets | $534.7M | $747.2M | ||
| Property and equipment, net | $5.3M | $4.3M | ||
| Operating lease right-of-use assets, net | $2.4M | $3.9M | ||
| Intangible assets | $27.2M | $27.2M | ||
| Other assets | $13.4M | $9.7M | ||
| Total assets | $583.0M | $792.3M | ||
| Accounts payable | $1.2M | $3.3M | ||
| Accrued expenses | $47.0M | $33.8M | ||
| Current portion of operating lease liabilities | $1.6M | $1.5M | ||
| Current portion of long-term liabilities | $1.2M | $942.0K | ||
| Total current liabilities | $51.0M | $39.5M | ||
| Long-term portion of operating lease liabilities | $784.0K | $2.4M | ||
| Other long-term liabilities | $4.0M | $3.5M | ||
| Total liabilities | $55.8M | $45.3M | ||
| Common stock, $.001 par value; 297,000,000 shares authorized; 66,549,442 and 66,374,549 shares issued and outstanding at December 31, 2025 and 2024, respectively | $67.0K | $66.0K | ||
| Additional paid-in capital | $2.3B | $2.3B | ||
| Accumulated other comprehensive income | $3.6M | $3.3M | ||
| Accumulated deficit | -$1.8B | -$1.6B | ||
| Total stockholders' equity | $527.2M | $747.0M | $429.2M | $326.2M |
| Total liabilities and stockholders' equity | $583.0M | $792.3M | ||
| Convertible preferred stock, par value (in dollars per share) | $0.01 | $0.01 | ||
| Convertible preferred stock, shares authorized (in shares) | 3.0M shares | 3.0M shares | ||
| Convertible preferred stock, shares issued (in shares) | 0 shares | 0 shares | ||
| Convertible preferred stock, shares outstanding (in shares) | 0 shares | 0 shares | ||
| Common stock, par value (in dollars per share) | $0.00 | $0.00 | ||
| Common stock, shares authorized (in shares) | 297.0M shares | 297.0M shares | ||
| Common stock, shares issued (in shares) | 66.5M shares | 66.4M shares | ||
| Common stock, shares outstanding (in shares) | 66.5M shares | 66.4M shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $28.9M | $28.4M | ||
| Marketable securities | $489.7M | $696.9M | ||
| Accounts and other receivables | $2.0M | $700.0K | ||
| Prepaid and other current assets | $14.1M | $21.2M | ||
| Total current assets | $534.7M | $747.2M | ||
| Property and equipment, net | $5.3M | $4.3M | ||
| Operating lease right-of-use assets, net | $2.4M | $3.9M | ||
| Intangible assets | $27.2M | $27.2M | ||
| Other assets | $13.4M | $9.7M | ||
| Total assets | $583.0M | $792.3M | ||
| Accounts payable | $1.2M | $3.3M | ||
| Accrued expenses | $47.0M | $33.8M | ||
| Current portion of operating lease liabilities | $1.6M | $1.5M | ||
| Current portion of long-term liabilities | $1.2M | $942.0K | ||
| Total current liabilities | $51.0M | $39.5M | ||
| Long-term portion of operating lease liabilities | $784.0K | $2.4M | ||
| Other long-term liabilities | $4.0M | $3.5M | ||
| Total liabilities | $55.8M | $45.3M | ||
| Common stock, $.001 par value; 297,000,000 shares authorized; 66,549,442 and 66,374,549 shares issued and outstanding at December 31, 2025 and 2024, respectively | $67.0K | $66.0K | ||
| Additional paid-in capital | $2.3B | $2.3B | ||
| Accumulated other comprehensive income | $3.6M | $3.3M | ||
| Accumulated deficit | -$1.8B | -$1.6B | ||
| Total stockholders' equity | $527.2M | $747.0M | $429.2M | $326.2M |
| Total liabilities and stockholders' equity | $583.0M | $792.3M | ||
| Convertible preferred stock, par value (in dollars per share) | $0.01 | $0.01 | ||
| Convertible preferred stock, shares authorized (in shares) | 3.0M shares | 3.0M shares | ||
| Convertible preferred stock, shares issued (in shares) | 0 shares | 0 shares | ||
| Convertible preferred stock, shares outstanding (in shares) | 0 shares | 0 shares | ||
| Common stock, par value (in dollars per share) | $0.00 | $0.00 | ||
| Common stock, shares authorized (in shares) | 297.0M shares | 297.0M shares | ||
| Common stock, shares issued (in shares) | 66.5M shares | 66.4M shares | ||
| Common stock, shares outstanding (in shares) | 66.5M shares | 66.4M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 3 fiscal years, latest first.5
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net loss | -$258.8M | -$157.9M | -$141.4M |
| Depreciation and amortization | $3.4M | $3.2M | $3.0M |
| Amortization and premium of marketable securities, net | -$5.9M | -$15.7M | -$6.2M |
| Loss on disposal of assets | $12.0K | $16.0K | |
| Stock-based compensation expense | $36.2M | $34.2M | $23.9M |
| Accounts and other receivables | -$1.3M | $1.9M | -$2.3M |
| Prepaid and other current assets | $8.7M | -$19.9M | $5.9M |
| Other assets | -$3.6M | -$9.6M | -$3.0K |
| Accounts payable and accrued expenses | $11.0M | $11.6M | $9.4M |
| Other liabilities | -$753.0K | -$5.6M | $462.0K |
| Net cash used in operating activities | -$210.9M | -$157.8M | -$107.3M |
| Sales and maturities of marketable securities | $596.3M | $501.7M | $320.6M |
| Purchases of marketable securities | -$384.5M | -$789.9M | -$424.6M |
| Acquisition of property and equipment | -$2.7M | -$1.9M | -$1.8M |
| Net cash provided by (used in) investing activities | $209.1M | -$290.1M | -$105.8M |
| Net proceeds from stock issuances | $432.3M | $216.2M | |
| Proceeds from issuance of stock from employee benefit plans | $2.4M | $9.2M | $2.2M |
| Net cash provided by financing activities | $2.4M | $441.4M | $218.5M |
| Net increase (decrease) in cash and cash equivalents | $515.0K | -$6.5M | $5.4M |
| Accrued construction in progress | $98.0K | $27.0K | $77.0K |
No quarter-by-quarter statement was filed.
Leadership
Who has led Celldex Therapeutics, and when. Pick a name to see everywhere that person has worked.
Chief executive
Chief financial officer
1990200020102020
- Chief executive officerAnthony S. Marucci Jan 8, 2009 to now13
- Chief executive officerUna S. Ryan Jan 5, 2006 to Mar 11, 200814
- PresidentAnthony S. Marucci Jan 8, 2009 to now13
- PresidentUna S. Ryan Jan 5, 2006 to Mar 11, 200814
- Chief financial officerSamuel Bates Martin Jul 5, 2017 to now15
- Chief financial officerAvery W. Catlin Jan 10, 2006 to Sep 7, 201616
Board members and other officers (35)
- SVP & Chief Commercial OfficerTeri L. Lawver Nov 12, 2025 to now17
- SVP, Chief Medical OfficerDiane C. Young Jul 8, 2019 to now18
- SVP of Corp Affairs & Admin.Sarah Cavanaugh Jun 16, 2017 to now19
- SVP of Regulatory AffairsMargo Heath-Chiozzi Oct 3, 2017 to now20
- SVP, Chief Product Dev OfficerElizabeth Crowley Aug 12, 2016 to now21
- SVP, Reg. & Precision MedicineTheresa Lavallee Dec 5, 2016 to Dec 15, 201622
- Sr. VP & CCORichard M. Wright Jul 1, 2015 to Jun 17, 202423
- Sr. VP & CBORonald Pepin Jul 6, 2011 to now24
- Exec. VP & Corporate Dev.Anthony S. Marucci Mar 17, 2008 to Mar 17, 200825
- Senior VP, Business Dev.Ronald C. Newbold Mar 17, 2008 to Jan 8, 200926
- Sen. VP & Ch Scientific Off.Tibor Keler Mar 17, 2008 to now27
- Sen. VP & Ch. Medical OfficerThomas Andrew Davis Mar 25, 2008 to Jun 16, 201728
- V.P. ResearchHenry C. Marsh Jr. Jan 10, 2006 to Mar 11, 200829
- Sr VP R&DRonald W. Ellis Jan 25, 2006 to Jan 8, 200730
- Board memberDenice Torres Jun 6, 2025 to now31
- Board memberRita Jain Feb 21, 2023 to now32
- Board memberCheryl Cohen Jun 17, 2022 to now33
- Board memberGarry Arthur Neil Jun 17, 2022 to now34
- Board memberJames J. Marino Mar 1, 2017 to now35
- Board memberKeith L. Brownlie Jun 16, 2017 to now36
- Board memberGerald McMahon Phd. Dec 15, 2016 to Dec 4, 201837
- Board memberAnthony S. Marucci Aug 10, 2011 to now38
- Board memberTimothy M. Shannon Oct 6, 2009 to Jun 5, 201439
- Board memberCharles R. Schaller Mar 17, 2008 to Sep 13, 201040
- Board memberGeorge Elston Mar 17, 2008 to Jun 9, 201641
- Board memberHerbert J. Conrad Mar 17, 2008 to now42
- Board memberRajesh R. Parekh Mar 17, 2008 to Sep 22, 201043
- Board memberUna S. Ryan Jan 5, 2006 to Mar 11, 200814
- Board memberKaren Shoos Lipton May 17, 2006 to Jun 17, 202444
- Board memberAlf A. Lindberg May 26, 2006 to May 25, 200745
- Board memberHarry Penner Jr. May 26, 2006 to now46
- Board memberJ. Barrie Ward May 26, 2006 to May 26, 200647
- Board memberPeter A. Sears May 26, 2006 to May 25, 200748
- Board memberLarry Ellberger May 30, 2006 to Jun 15, 201849
- General counselFreddy A. Jimenez Jan 4, 2021 to now50
Former names
Timeline
Filings
282 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 37 major events, 131 insider forms, 61 large holders, 33 other. The latest 20:
- Oct 7, 2026SCHEDULE 13G/A EDGAR
- Sep 22, 20268-K EDGAR
- Aug 14, 2026SCHEDULE 13G/A EDGAR
- Aug 14, 2026SCHEDULE 13G EDGAR
- Aug 6, 20268-K EDGAR
- Aug 6, 202610-Q EDGAR
- Jul 15, 20268-K EDGAR
- Jun 29, 20264 EDGAR
- Jun 29, 20264 EDGAR
- Jun 29, 20264 EDGAR
- Jun 29, 20264 EDGAR
- Jun 29, 20264 EDGAR
- Jun 29, 20264 EDGAR
- Jun 29, 20264 EDGAR
- Jun 29, 20264 EDGAR
- Jun 29, 20264 EDGAR
- Jun 29, 20264 EDGAR
- Jun 29, 20264 EDGAR
- Jun 29, 20264 EDGAR
- Jun 29, 20264 EDGAR
The 282 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last three years, summarized. The full record is on SEC EDGAR.
Insider trades and holders
Large holders
Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 61 such filings since October 2021, the latest 10:
- Oct 7, 2026SCHEDULE 13G/A
- Aug 14, 2026SCHEDULE 13G/A
- Aug 14, 2026SCHEDULE 13G
- May 15, 2026SCHEDULE 13G/A
- May 15, 2026SCHEDULE 13G/A
- May 12, 2026SCHEDULE 13G
- May 6, 2026SCHEDULE 13G/A
- Apr 29, 2026SCHEDULE 13G
- Mar 26, 2026SCHEDULE 13G/A
- Mar 10, 2026SCHEDULE 13G/A
From Forms 4 and Schedules 13D and 13G filed with the SEC.
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| Wellington Management Group Llp | 9,543,671 | $355.1M | 0.1% | +983,195 |
| BlackRock, Inc. | 7,002,530 | $260.6M | 0.0% | +1,632,645 |
| Kynam Capital Management, LP | 5,322,908 | $198.1M | 10.9% | −517,659 |
| State Street Corp | 3,900,427 | $145.1M | 0.0% | +1,096,259 |
| Fmr LLC | 3,722,888 | $138.5M | 0.0% | −26,160 |
| Vanguard Capital Management LLC | 3,464,831 | $128.9M | 0.0% | +503,936 |
| Deep Track Capital, LP | 2,939,151 | $109.4M | 1.6% | +1,655,172 |
| Logos Global Management LP | 2,100,000 | $78.1M | 3.4% | +1,650,000 |
| Geode Capital Management, LLC | 2,022,226 | $75.3M | 0.0% | +334,152 |
| Eversept Partners, LP | 1,785,941 | $66.5M | 3.6% | −2,075 |
| Goldman Sachs Group Inc | 1,615,343 | $60.1M | 0.0% | +626,927 |
| Assenagon Asset Management S.A. | 1,577,392 | $58.7M | 0.0% | +1,430,867 |
| Commodore Capital LP | 1,350,000 | $50.2M | 3.0% | −1,346,616 |
| Bellevue Group AG | 1,200,000 | $44.7M | 0.9% | No change |
| Baker Bros. Advisors LP | 1,182,611 | $44.0M | 0.2% | +517,241 |
| Millennium Management LLC | 1,170,787 | $43.6M | 0.0% | −82,745 |
| Dimensional Fund Advisors LP | 1,073,985 | $40.0M | 0.0% | +14,451 |
| American Century Companies Inc | 1,042,395 | $38.8M | 0.0% | +186,085 |
| Eventide Asset Management, LLC | 1,037,000 | $38.6M | 0.5% | No change |
| Novo Holdings A/s | 1,025,000 | $38.1M | 2.2% | −175,000 |
| Elmind Capital, LP | 990,000 | $36.8M | 9.3% | +125,000 |
| Driehaus Capital Management LLC | 989,442 | $36.8M | 0.2% | New |
| Fisher Asset Management, LLC | 985,677 | $36.7M | 0.0% | −27,971 |
| Pictet Asset Management Holding SA | 917,408 | $34.1M | 0.0% | −6,288 |
| Foresite Capital Management VI LLC | 879,713 | $32.7M | 5.1% | +563,800 |
13F reports cover disclosed long positions in U.S. stocks only.
Links
- Websitewww.celldex.com1
- LinkedInwww.linkedin.com/company/celldex1
- WikidataQ30281437
- SEC EDGARCIK 744218
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1WikidataCelldex Therapeutics on Wikidata
- 2
- 3Company websiteCelldex Therapeutics logo
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14SEC EDGARUna S. Ryan, Chief executive officer
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23SEC EDGARRichard M. Wright, Sr. VP & CCO
- 24SEC EDGARRonald Pepin, Sr. VP & CBO
- 25
- 26
- 27
- 28
- 29SEC EDGARHenry C. Marsh Jr., V.P. Research
- 30SEC EDGARRonald W. Ellis, Sr VP R&D
- 31SEC EDGARDenice Torres, Board member
- 32SEC EDGARRita Jain, Board member
- 33SEC EDGARCheryl Cohen, Board member
- 34SEC EDGARGarry Arthur Neil, Board member
- 35SEC EDGARJames J. Marino, Board member
- 36SEC EDGARKeith L. Brownlie, Board member
- 37SEC EDGARGerald McMahon Phd., Board member
- 38SEC EDGARAnthony S. Marucci, Board member
- 39SEC EDGARTimothy M. Shannon, Board member
- 40SEC EDGARCharles R. Schaller, Board member
- 41SEC EDGARGeorge Elston, Board member
- 42SEC EDGARHerbert J. Conrad, Board member
- 43SEC EDGARRajesh R. Parekh, Board member
- 44SEC EDGARKaren Shoos Lipton, Board member
- 45SEC EDGARAlf A. Lindberg, Board member
- 46SEC EDGARHarry Penner Jr., Board member
- 47SEC EDGARJ. Barrie Ward, Board member
- 48SEC EDGARPeter A. Sears, Board member
- 49SEC EDGARLarry Ellberger, Board member
- 50SEC EDGARFreddy A. Jimenez, General counsel